Legend Biotech (LEGN) Cash from Discontinued Operations (2023 - 2025)
Legend Biotech (LEGN) reported Cash from Discontinued Operations of 106286000.0 for Q1 2025, down 4558.31% on a YoY basis from 2384000.0 in Q1 2024, and down 29.49% quarter-over-quarter from 82078000.0 in Q4 2024.
Legend Biotech (LEGN) Cash from Discontinued Operations (2023 - 2025) Analysis & Trends
Legend Biotech has reported Cash from Discontinued Operations for 3 years, with the latest figure at 106286000.0 in Q1 2025.
- For the quarter ending Q1 2025, Cash from Discontinued Operations fell 4558.31% year-over-year to 106286000.0; the trailing twelve-month figure through Mar 2025 stood at 281625000.0 (changed N/A YoY), and the FY2024 full-year result was 144033000.0, up 63.38% from the prior year.
- Cash from Discontinued Operations for Q1 2025 stood at 106286000.0, down from 82078000.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 2384000.0 in Q1 2024, with the low at 106286000.0 in Q1 2025.
- Historically, Cash from Discontinued Operations has averaged 70406250.0 across 3 years, with a median of 88861500.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Discontinued Operations climbed 14.18% — and 2025, when it plunged 4558.31%.
- Legend Biotech's Cash from Discontinued Operations stood at 95645000.0 in 2023, then advanced by 14.18% to 82078000.0 in 2024, then retreated by 29.49% to 106286000.0 in 2025.
- The last three Cash from Discontinued Operations figures came in at 106286000.0 (Q1 2025), 82078000.0 (Q4 2024), and 2384000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -59.14 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -106.29 Mn |
| Mar 31, 2025 | -106.29 Mn |
| Dec 31, 2024 | -82.08 Mn |
| Dec 31, 2024 | -82.08 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Dec 31, 2023 | -95.65 Mn |
| Dec 31, 2023 | -95.65 Mn |